ImmunityBio (IBRX) has moved back into focus after releasing preliminary Q1 2026 net product revenue of about US$44.2 million, with management tying the performance to ANKTIVA uptake, broader ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or ...

Back in 2016, hundreds of jobs were expected for a drug manufacturing plant in the town of Dunkirk. The plant was built but ...

Shiong’s earlier appearance on The Sean Spicer Show as suggesting uses beyond Anktiva’s approved indication. ・Soon-Shiong said the FDA classified the podcast discussion as direct-to-consumer ...

We recently compiled a list of the 10 Best Mid Cap Stocks to Invest In According to Billionaires. ImmunityBio, Inc.

Levi & Korsinsky, LLP encourages investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) to contact the firm.

Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (“ImmunityBio” or the C ...

Among the measures ImmunityBio has implemented are “expanded promotional review protocols,” executive training and external ...

On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

If you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877 ...

If you have suffered a loss on your ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or ...

Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase ...